48th Annual ICAAC / IDSA
46th Annual Meeting
October 25-28, 2008, Washington, DC

During the 48th ICAAC/46th IDSA conference new data was presented which provides additional guidance to clinicians regarding:

• When to start ARV therapy.

• Which boosted PIs should be used preferentially in initial therapy and whether some of the newer drugs now should be considered for use in treatment-naïve patients.

• Further studies establishing the safety and efficacy of simplifying ARV therapy with a one pill, once daily regimen or using a decreased dose of ritonavir when boosting some PIs.

• Several drugs in the HIV pipeline with key data indicating their progress in development.

This program is sponsored for CME credit by Rush University Medical Center.
The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Association of Nurses in AIDS Care (ANAC) is an approved provider of continuing education in nursing by the Virginia Nurses Association Continuing Education Approval Committee, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Supported by an independent educational grant from Gilead Sciences Medical Affairs.
*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings from the 48th Annual ICAAC/IDSA 46th Annual Meeting.